APYI — Arypsa Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -121.18% | ||
| Return on Equity | -106.04% | ||
| Operating Margin | -67.03% | ||
Financial Summary
| Year End 31st Dec | Unit | 2004 | 2005 | 2006 | 2007 | 2008 | 2009E | 2010E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.66 | 7.21 | 12.69 | 10.27 | 8.53 | n/a | n/a | 2.93% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +77.14 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arypsa, Inc. is a clinical information and diagnostic systems solutions company. The Company is a provider of healthcare products and services for the laboratory and imaging marketplaces. The Company is engaged in providing engineered workflow solutions that include software, interfaces, hardware and professional services to an array of markets encompassing specialty labs, reference labs, clinics, hospitals, imaging centers and orthopedic practices. The Company's engineered systems are integrated and customized to provide a single-vendor or enterprise-wide solution. The Company’s products include laboratory solutions and imaging solutions. It offers laboratory solutions for clinics, hospitals, reference laboratories and specialty laboratories of all types. The Company offers imaging solutions for hospitals, imaging departments and centers, multi-specialty clinics and orthopedic environments.
Directors
- James Zierick CHM (54)
- Ademola Lawal CEO (35)
- Marina Varela CAO (39)
- Jeffrey Tumbleson DRC (43)
- Norman Cohen IND (74)
- Robert Fogerson IND (58)
- Lawrence Schmid IND (69)
- Last Annual
- December 31st, 2008
- Last Interim
- September 30th, 2009
- Incorporated
- April 27th, 1978
- Public Since
- September 23rd, 1983
- No. of Shareholders
- 975
- No. of Employees
- 69
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 170,310
- Address
- 4360 Park Terrace Dr Ste 220, WESTLAKE VILLAGE, 91361
- Web
- http://aspyra.com
- Phone
- +1 8188806700
- Auditors
- BDO Seidman
Similar to APYI
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 19:22 UTC, shares in Arypsa are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Arypsa last closed at $0.00 and the price had moved by -99.6% over the past 365 days. In terms of relative price strength the Arypsa share price has underperformed the S&P500 Index by -99.63% over the past year.
There is no consensus recommendation for this security.
Find out moreArypsa does not currently pay a dividend.
Arypsa does not currently pay a dividend.
Arypsa does not currently pay a dividend.
To buy shares in Arypsa you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Arypsa had a market capitalisation of .
Here are the trading details for Arypsa:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: APYI
Based on an overall assessment of its quality, value and momentum Arypsa is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arypsa. Over the past six months, its share price has underperformed the S&P500 Index by -99.59%.
As of the last closing price of $0.00, shares in Arypsa were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Arypsa PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Arypsa's management team is headed by:
- James Zierick - CHM
- Ademola Lawal - CEO
- Marina Varela - CAO
- Jeffrey Tumbleson - DRC
- Norman Cohen - IND
- Robert Fogerson - IND
- Lawrence Schmid - IND